Wearables have become a major driver of innovation in personalized healthcare. In particular, neurotechnology is opening up entirely new possibilities – from brain-computer interfaces to mental health monitoring and neurofeedback. A central element of these systems are electrodes, which form the interface between the human body and electronic components.

Datwyler generated revenue of CHF 1'107.7 million and increased its adjusted EBIT margin to 10.7% in 2024, despite weak markets and tangibly negative currency effects. Solid free cash flow allows an unchanged cash dividend of CHF 3.20 per bearer share to be proposed to the Annual General Meeting. The «ForwardNow» transformation program will accelerate the planned growth in revenue and profitability. The one-off costs associated with this program had a negative impact of CHF 37.9 million on the result in the reporting year, with the reported EBIT amounting to CHF 80.2 million. Over the medium-term and in a normal operating environment, the company expects annual organic revenue growth in the higher single-digit percentage range and an EBIT margin of 17% plus. In light of market forecasts, Datwyler is cautiously optimistic and expects to see a continuous increase in revenue and profitability.

Strong project pipeline as the basis for scaling the business model

Despite the almost complete loss of the high-margin COVID business and a significantly negative currency effect, Datwyler achieved constant revenue of CHF 1’151.5 million and an EBIT margin of 10.5% in 2023. The Annual General Meeting will be asked to approve a cash dividend of CHF 3.20 per bearer share. Despite a challenging environment, Datwyler is cautiously optimistic for 2024 and aims to achieve low single-digit percentage organic revenue growth and an improved EBIT margin. Based on the strong project pipeline, the focus for the future is clearly set on profitable organic growth by scaling the business model and production capacities.

Datwyler, the specialist for system critical elastomeric components, is proud to announce that our Wearable Sensor Expert Dr. Mattia A. Lucchini will present «smartlink: softpulse – Soft dry electrodes for bio-monitoring» at the Medical Fair Asia.

**Innovation projects and Swiss plant are the focus of the Capital Market Day.** Thanks to strong positions in attractive markets and leading core competencies, Datwyler enjoys a high demand. Datwyler is expanding its production capacity with targeted investments and laying the foundation for further profitable growth. The focus at the Capital Market Day will be on the company’s innovation projects and the highly automated Swiss plant in Schattdorf. Following completion of the Reichelt sale, the previous annual targets for revenue and EBIT margin have undergone slight adjustments. Datwyler has for the first time defined growth and EBIT targets for the three-year period from 2022 to 2024.